Search clinical trials for: Placebo for ABT-126

Total 4066 results

Abbott

Completed

Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia

Schizophrenia

United States
AbbVie (prior sponsor, Abbott)

Completed

A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

Schizophrenia

United States
AbbVie (prior sponsor, Abbott)

Completed

Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Cognitive Deficits in Schizophrenia

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

Schizophrenia

United States, Russian Federation, United Kingdom
Abbott

Completed

Pharmacokinetic Study of ABT-126 in Healthy Volunteers

Healthy Volunteers

United States
Abbott

Completed

Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in Healthy Volunteers

Healthy

United States
Abbott

Completed

A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease

Alzheimer's Disease

United States
AbbVie (prior sponsor, Abbott)

Completed

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Alzheimer's Disease

United States, Canada, France, Germany, Greece, South Africa, United Kingdom
Abbott

Completed

A Safety and Tolerability Study of ABT-126 in Elderly

Alzheimer's Disease

United States
AbbVie (prior sponsor, Abbott)

Terminated

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States, Poland, Russian Federation, South Africa, Ukraine, United Kingdom
AbbVie

Terminated

Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

Schizophrenia

United States, Russian Federation, United Kingdom
AbbVie

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Research Foundation for Mental Hygiene, Inc.

Completed

Attention-Bias Modification Treatment for PTSD

Posttraumatic Stress Disorder (PTSD)

United States
AbbVie

Completed

A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis

Erosive Hand Osteoarthritis
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

Chronic Hepatitis C Infection
AbbVie

Terminated

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Alzheimer's Disease

United States
Ariston Pharmaceuticals, Inc.

Unknown

Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine

Migraine | Migraine Disorders | Migraine Headache | Migraine Without Aura | Migraine With Aura

Finland, Netherlands, United Kingdom
AbbVie (prior sponsor, Abbott)

Terminated

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States, Canada, France, Germany, Greece, South Africa, United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection

Chronic Hepatitis C Infection
Asahi Kasei Pharma Corporation

Completed

Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Japan
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection (ENDURANCE-2)

Chronic Hepatitis C Virus (HCV) Infection
Mitsubishi Tanabe Pharma Corporation
Kureha Corporation

Completed

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)

Chronic Kidney Disease

United States, France, Italy, Ukraine, Argentina, Mexico, Poland, Canada, Brazil, Russian Federation, Czechia, Puerto Rico
Mitsubishi Tanabe Pharma Corporation
Kureha Corporation

Completed

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)

Chronic Kidney Disease

United States, Poland, Ukraine, Spain, Argentina, Mexico, Canada, Brazil, Russian Federation, Puerto Rico, Germany, Czechia
Asahi Kasei Pharma America Corporation

Withdrawn

The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy (Scarlet2)

Sepsis and Coagulopathy
Asahi Kasei Pharma Corporation

Completed

Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer

Postoperative Stage II/III Colon Cancer

Japan
Assembly Biosciences

Completed

A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Australia, United States, Hong Kong, United Kingdom, China, New Zealand
Applied Molecular Transport

Completed

SAD Study to Assess the Safety, Tolerability, PK, and In-Vivo Performance of AMT-126 in Healthy Male and Female Subjects

Healthy Volunteers

United Kingdom
Asahi Kasei Pharma America Corporation

Completed

Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy

Severe Sepsis | Coagulopathy

Korea, Republic of, United States, Taiwan, Netherlands, United Kingdom, Australia, Canada, Belgium, Israel, Spain, New Zealand, France, Brazil, India, Argentina, Bulgaria, Croatia, Czechia, Finland, Germany, Hungary, Peru, Russian Federation and more
University of Sao Paulo General Hospital
Fundação de Amparo à Pesquisa do Estado de São Paulo

Completed

Acceptance and Commitment Therapy for Insomnia (ACT-I)

Insomnia

Brazil
Abbott

Completed

Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers

HCV Infection

United States
AbbVie

Active, not recruiting

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (TRANSFORM-1)

Myelofibrosis (MF)

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Spain, Sweden, Taiwan, Turkey and more
Kamada, Ltd.

Completed

Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"

Alpha-1 Antitrypsin Deficiency

United States
UniQure Biopharma B.V.

Not yet recruiting

Safety, Tolerability, and Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Amyotrophic Lateral Sclerosis (ALS) Patients With SOD1 Mutations

Amyotrophic Lateral Sclerosis
Ocera Therapeutics

Completed

Safety and Efficacy of AST-120 in the Treatment of Pouchitis

Pouchitis

United States
Brigham and Women's Hospital
Boston Medical Center

Recruiting

NAD Augmentation in Diabetes Kidney Disease (DKD)

Diabetic Kidney Disease | Type2diabetes

United States
Karolinska Institutet
Region Stockholm

Completed

New Clinical Applications for Internet-based Cognitive Behavior Therapy for Insomnia and Depression

Insomnia | Major Depression | Minor Depression

Sweden
Artisan Pharma, Inc.

Completed

Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation

Sepsis | Disseminated Intravascular Coagulation

United States, Canada, Thailand, Malaysia
Conmed Pharmaceutical & Bio-Medical Corporation
Chang Gung Memorial Hospital; Kaohsiung Medical University; Tri-Service General... and other collaborators

Completed

AST-120 in Hemodialysis Patients With Uremic Pruritus (AST-120)

Uremic Pruritus

Taiwan
Abbott

Completed

Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
AbbVie

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection (PEARL-IV)

Chronic Hepatitis C Infection
University Health Network, Toronto

Completed

Integrated Treatment for Co-occurring Eating Disorders and Posttraumatic Stress Disorder

Eating Disorder | PostTraumatic Stress Disorder

Canada
Abbott

Completed

Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

Arthritis | Psoriatic
AbbVie

Completed

Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1

HCV Infection

United States
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Cognitive Deficits in Schizophrenia

United States
Rambam Health Care Campus

Completed

Green Tea Effect on Anthropometric, Oxidation and Inflammation Parameters in Physically Active vs. Sedentary Elders (GT)

Aging

Israel
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Advanced or Metastatic Non-Small Cell Lung Cancer

United States, Australia, Brazil, Czech Republic, Russian Federation, Singapore
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection (PEARL-III)

Chronic Hepatitis C Infection
AbbVie

Completed

Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects

HCV Infection
AbbVie (prior sponsor, Abbott)

Completed

Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Abbott

Completed

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness

Sleep Disorder

United States

3

Subscribe